{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:05:02Z","timestamp":1792098302853,"version":"4.4.0"},"reference-count":408,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.neuropharm.2013.07.004","type":"journal-article","created":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T01:54:46Z","timestamp":1374717286000},"page":"27-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":650,"special_numbering":"PA","title":["Therapeutics of Alzheimer's disease: Past, present and future"],"prefix":"10.1016","volume":"76","author":[{"given":"R.","family":"Anand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran Dip","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas Ali","family":"Mahdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.07.004_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s12603-012-0393-5","volume":"16","year":"2012","journal-title":"The Journal of Nutrition, Health & Aging"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuron.2008.06.018","article-title":"Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta","volume":"59","author":"Adlard","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib4","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","article-title":"An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta","volume":"32","author":"Adolfsson","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.etp.2010.11.012","article-title":"Modulatory effects of vitamin E, acetyl-L-carnitine and alpha-lipoic acid on new potential biomarkers for Alzheimer's disease in rat model","volume":"64","author":"Ahmed","year":"2012","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer's disease \u2013 a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib7","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib8","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jama.300.15.1774","article-title":"High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial","volume":"300","author":"Aisen","year":"2008","journal-title":"JAMA"},{"issue":"Suppl.\u00a0A","key":"10.1016\/j.neuropharm.2013.07.004_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1358\/dot.2012.48(Suppl.A).1739721","article-title":"Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia","volume":"48","author":"Allegri","year":"2012","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib10","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.biopsych.2006.03.048","article-title":"Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia","volume":"60","author":"Andrieux","year":"2006","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.neuropharm.2013.07.004_bib11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/jnc.12306","article-title":"Novel contribution of cell surface and intracellular M1-muscarinic acetylcholine receptors to synaptic plasticity in hippocampus","volume":"126","author":"Anisuzzaman","year":"2013","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1358\/dot.2011.47.7.1656496","article-title":"Cerebrolysin in Alzheimer's disease","volume":"47","author":"Anton Alvarez","year":"2011","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib13","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.104.077172","article-title":"Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons","volume":"312","author":"Aracava","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib14","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1038\/sj.emboj.7600415","article-title":"RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice","volume":"23","author":"Arancio","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3233\/JAD-2009-1087","article-title":"Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice","volume":"17","author":"Arendash","year":"2009","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pharmthera.2009.09.001","article-title":"Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA","volume":"125","author":"Atack","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1096\/fj.07-9610com","article-title":"Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways","volume":"22","author":"Atamna","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/alzrt160","article-title":"Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy","volume":"5","author":"Atri","year":"2013","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-0173(03)00174-7","article-title":"Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta","volume":"43","author":"Atwood","year":"2003","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1749-6632.2001.tb03654.x","article-title":"Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer","volume":"939","author":"Bachurin","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib21","doi-asserted-by":"crossref","first-page":"e58837","DOI":"10.1371\/journal.pone.0058837","article-title":"The proton-pump inhibitor lansoprazole enhances amyloid beta production","volume":"8","author":"Badiola","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib22","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.2174\/092986711797535245","article-title":"Multi-target-directed ligands in Alzheimer's disease treatment","volume":"18","author":"Bajda","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JAD-2008-13110","article-title":"Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study","volume":"13","author":"Bakchine","year":"2008","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17070","article-title":"Study of the use of antidepressants for depression in dementia: the HTA-SADD trial\u2013a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine","volume":"17","author":"Banerjee","year":"2013","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib25","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1089\/ars.2006.8.2047","article-title":"Reproductive hormones modulate oxidative stress in Alzheimer's disease","volume":"8","author":"Barron","year":"2006","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/jcp.0b013e318160862c","article-title":"Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease","volume":"28","author":"Baum","year":"2008","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib27","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1096\/fasebj.6.15.1464368","article-title":"Mechanisms of excitotoxicity in neurologic diseases","volume":"6","author":"Beal","year":"1992","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib28","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00018-008-7462-2","article-title":"Substrate specificity of gamma-secretase and other intramembrane proteases","volume":"65","author":"Beel","year":"2008","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/clpt.1983.222","article-title":"Cotinine disposition and effects","volume":"34","author":"Benowitz","year":"1983","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0149-7634(03)00070-8","article-title":"The cholinergic basal forebrain system during development and its influence on cognitive processes: important questions and potential answers","volume":"27","author":"Berger-Sweeney","year":"2003","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JAD-2004-6103","article-title":"Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease","volume":"6","author":"Bilikiewicz","year":"2004","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib32","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib33","doi-asserted-by":"crossref","first-page":"e10405","DOI":"10.1371\/journal.pone.0010405","article-title":"Effects of long-term pioglitazone treatment on peripheral and central markers of aging","volume":"5","author":"Blalock","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib34","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","article-title":"Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease","volume":"69","author":"Blennow","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib36","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.expneurol.2010.05.010","article-title":"Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice","volume":"224","author":"Boimel","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0006-8993(98)00461-2","article-title":"Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid","volume":"799","author":"Bondy","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib38","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1471-4159.2004.02980.x","article-title":"Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones","volume":"92","author":"Bosel","year":"2005","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib39","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1471-4159.2011.07337.x","article-title":"Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain","volume":"118","author":"Boutajangout","year":"2011","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib40","first-page":"306","article-title":"Studies on the metabolism of (-)-cotinine in the human","volume":"135","author":"Bowman","year":"1962","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1124\/jpet.110.166876","article-title":"Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease","volume":"336","author":"Brioni","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","article-title":"Forecasting the global burden of Alzheimer's disease","volume":"3","author":"Brookmeyer","year":"2007","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bbr.2011.01.021","article-title":"Cholinergic influences on cortical development and adult neurogenesis","volume":"221","author":"Bruel-Jungerman","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib44","doi-asserted-by":"crossref","first-page":"13861","DOI":"10.1523\/JNEUROSCI.3059-10.2010","article-title":"Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy","volume":"30","author":"Brunden","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","article-title":"Tau protein isoforms, phosphorylation and role in neurodegenerative disorders","volume":"33","author":"Buee","year":"2000","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib46","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1124\/mol.53.3.555","article-title":"Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor","volume":"53","author":"Buisson","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3233\/JAD-2004-6302","article-title":"Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4","volume":"6","author":"Burkhardt","year":"2004","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib48","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2165\/00023210-200317090-00004","article-title":"The glutamatergic system and Alzheimer's disease: therapeutic implications","volume":"17","author":"Butterfield","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib49","doi-asserted-by":"crossref","first-page":"a50","DOI":"10.2741\/buxbaum","article-title":"Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in\u00a0vitro and in patients","volume":"7","author":"Buxbaum","year":"2002","journal-title":"Front Biosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib50","doi-asserted-by":"crossref","first-page":"e5274","DOI":"10.1371\/journal.pone.0005274","article-title":"Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening","volume":"4","author":"Cabrol","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib51","doi-asserted-by":"crossref","first-page":"14741","DOI":"10.1523\/JNEUROSCI.3728-09.2009","article-title":"Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway","volume":"29","author":"Canas","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib52","doi-asserted-by":"crossref","first-page":"e37555","DOI":"10.1371\/journal.pone.0037555","article-title":"Intranasal \u201cpainless\u201d human nerve growth factors slows amyloid neurodegeneration and prevents memory deficits in App X PS1 mice","volume":"7","author":"Capsoni","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib53","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2174\/157015910792246209","article-title":"Clinical aspects of melatonin intervention in Alzheimer's disease progression","volume":"8","author":"Cardinali","year":"2010","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib54","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.bbadis.2006.01.008","article-title":"Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice","volume":"1762","author":"Casadesus","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pnpbp.2005.06.013","article-title":"Effects of selective neuronal nitric oxide synthase inhibition on sleep and wakefulness in the rat","volume":"30","author":"Cavas","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib56","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.M111.229633","article-title":"Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression","volume":"286","author":"Chai","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0006-8993(91)90748-K","article-title":"Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain\u2013a combined in situ hybridisation\/in\u00a0vitro receptor autoradiographic study","volume":"561","author":"Chalmers","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib58","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/1533317508325093","article-title":"Efficacy of a vitamin\/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension","volume":"23","author":"Chan","year":"2008","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib59","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1096\/fj.10-167213","article-title":"Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice","volume":"25","author":"Chang","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib60","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10522-008-9169-z","article-title":"Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer's disease","volume":"9","author":"Chauhan","year":"2008","journal-title":"Biogerontology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1358\/dnp.2010.23.2.1475899","article-title":"Therapeutic potential of histamine H3 receptor antagonists in dementias","volume":"23","author":"Chazot","year":"2010","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib62","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2174\/156652407783220741","article-title":"RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease","volume":"7","author":"Chen","year":"2007","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib63","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00213-010-1943-3","article-title":"Inhibition of phosphodiesterase-4 reverses memory deficits produced by Abeta25-35 or Abeta1-40 peptide in rats","volume":"212","author":"Cheng","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib64","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.2174\/1381612811319150015","article-title":"Novel penetrating cations for targeting mitochondria","volume":"19","author":"Chernyak","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib65","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1124\/mol.63.6.1322","article-title":"Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole","volume":"63","author":"Chien","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib66","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/j.1460-9568.2005.03993.x","article-title":"Enhancement of learning behaviour by a potent nitric oxide-guanylate cyclase activator YC-1","volume":"21","author":"Chien","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jnc.12059","article-title":"Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease","volume":"124","author":"Choi","year":"2013","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib68","doi-asserted-by":"crossref","first-page":"765","DOI":"10.33549\/physiolres.931121","article-title":"Differential effects of statins and alendronate on cholinesterases in serum and brain of rats","volume":"56","author":"Cibickova","year":"2007","journal-title":"Physiol. Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib69","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bbr.2007.12.012","article-title":"5-HT(7) receptors in the modulation of cognitive processes","volume":"195","author":"Cifariello","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib70","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3233\/JAD-122308","article-title":"Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease","volume":"35","author":"Claxton","year":"2013","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib71","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10072-011-0618-0","article-title":"Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study","volume":"33","author":"Clerici","year":"2012","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib72","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4161\/hv.4.6.6200","article-title":"Molecular and cellular mechanisms of DNA vaccines","volume":"4","author":"Coban","year":"2008","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib73","first-page":"7","article-title":"Manipulating thyroid status alters endoplasmic reticulum calcium homeostasis in rat cerebellum","volume":"50","author":"Cole","year":"2012","journal-title":"Indian J. Exp. Biol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib74","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/13543776.2013.769522","article-title":"Sigma receptor modulators: a patent review","volume":"23","author":"Collina","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib75","doi-asserted-by":"crossref","first-page":"12867","DOI":"10.1073\/pnas.0601075103","article-title":"NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease","volume":"103","author":"Colton","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib76","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4161\/auto.19048","article-title":"Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in\u00a0vitro and in\u00a0vivo","volume":"8","author":"Congdon","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib77","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)60330-X","article-title":"New set of Alzheimer's trials focus on prevention","volume":"381","author":"Corbyn","year":"2013","journal-title":"The Lancet"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib78","doi-asserted-by":"crossref","first-page":"34202","DOI":"10.1074\/jbc.M505268200","article-title":"Mechanisms of statin-mediated inhibition of small G-protein function","volume":"280","author":"Cordle","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib79","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1523\/JNEUROSCI.2544-04.2005","article-title":"3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses","volume":"25","author":"Cordle","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib80","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000075957","article-title":"Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population","volume":"23","author":"Cornelius","year":"2004","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib81","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jalz.2005.06.001","article-title":"Reduced risk of Alzheimer's disease with high folate intake: the Baltimore Longitudinal Study of Aging","volume":"1","author":"Corrada","year":"2005","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib82","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0006-3223(00)01101-X","article-title":"Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease","volume":"49","author":"Coyle","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib83","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.neuint.2011.02.010","article-title":"Oleuropein and derivatives from olives as Tau aggregation inhibitors","volume":"58","author":"Daccache","year":"2011","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib84","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.expneurol.2006.08.008","article-title":"Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice","volume":"203","author":"Dall'Igna","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib85","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1368-5031.2005.00769.x","article-title":"Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment","volume":"60","author":"Dantoine","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib86","doi-asserted-by":"crossref","first-page":"P425","DOI":"10.1016\/j.jalz.2009.04.950","article-title":"scyllo-inositol (ELND005) ameliorates amyloid pathology in an aggressive mouse model of Alzheimer's disease","volume":"5","author":"DaSilva","year":"2009","journal-title":"Alzheimer's Demen. the J. Alzheimer's Assoc."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib87","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib88","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/nen.0b013e318040cfa2","article-title":"Nitric oxide synthase 3-mediated neurodegeneration after intracerebral gene delivery","volume":"66","author":"de la Monte","year":"2007","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib89","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1172\/JCI58642","article-title":"A\u00a0multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease","volume":"122","author":"Deane","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib90","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1172\/JCI29715","article-title":"The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins","volume":"117","author":"Dickey","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib91","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3389\/fphys.2012.00464","article-title":"Postsynaptic receptors for amyloid-beta oligomers as mediators of neuronal damage in Alzheimer's disease","volume":"3","author":"Dinamarca","year":"2012","journal-title":"Front Physiol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib92","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40262-012-0005-x","article-title":"A\u00a0placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects","volume":"51","author":"Dockens","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib93","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","article-title":"Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease","volume":"75","author":"Dodel","year":"2004","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib94","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1474-4422(13)70014-0","article-title":"Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"12","author":"Dodel","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib95","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib96","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bbr.2010.11.037","article-title":"The cholinergic system and hippocampal plasticity","volume":"221","author":"Drever","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib97","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1093\/hmg\/dds355","article-title":"Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice","volume":"21","author":"Dumont","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib98","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1471-4159.2009.05970.x","article-title":"Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease","volume":"109","author":"Dumont","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2013.01.014","article-title":"Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data","author":"Dysken","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1755-5949.2012.00317.x","article-title":"Cotinine: a potential new therapeutic agent against Alzheimer's disease","volume":"18","author":"Echeverria","year":"2012","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib101","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3233\/JAD-2011-102136","article-title":"Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer's disease mice","volume":"24","author":"Echeverria","year":"2011","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib102","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/156720512800492530","article-title":"Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD","volume":"9","author":"Egan","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib103","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.neuroscience.2008.06.052","article-title":"Brain inflammation and adult neurogenesis: the dual role of microglia","volume":"158","author":"Ekdahl","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib104","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1471-4159.2006.04139.x","article-title":"Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert","volume":"99","author":"Engel","year":"2006","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000336051","article-title":"Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease","volume":"33","author":"Eriksdotter-Jonhagen","year":"2012","journal-title":"Dement Geriatr. Cogn. Disord."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib106","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1172\/JCI200318162","article-title":"NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in\u00a0vivo","volume":"112","author":"Eriksen","year":"2003","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib107","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3233\/JAD-2009-0920","article-title":"Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study","volume":"16","author":"Eskelinen","year":"2009","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib108","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/biof.37","article-title":"Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E","volume":"35","author":"Fan","year":"2009","journal-title":"Biofactors"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib109","first-page":"CD002854","article-title":"Vitamin E for Alzheimer's dementia and mild cognitive impairment","volume":"11","author":"Farina","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib110","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-000917","article-title":"Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review","volume":"2","author":"Farrimond","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib111","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib112","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","article-title":"Global prevalence of dementia: a Delphi consensus study","volume":"366","author":"Ferri","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib113","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.nurt.2008.05.002","article-title":"Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease","volume":"5","author":"Fisher","year":"2008","journal-title":"Neurotherapeutics"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2013.07.004_bib114","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1471-4159.2011.07507.x","article-title":"Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease","volume":"120","author":"Fisher","year":"2012","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12031-002-0025-3","article-title":"AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease","volume":"19","author":"Fisher","year":"2002","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib116","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/gt.2011.178","article-title":"Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer","volume":"19","author":"Fjord-Larsen","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib117","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","article-title":"Chronic divalproex sodium use and brain atrophy in Alzheimer disease","volume":"77","author":"Fleisher","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib118","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.expneurol.2009.09.013","article-title":"Cholesterol and statins in Alzheimer's disease: current controversies","volume":"223","author":"Fonseca","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib119","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","article-title":"Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease","volume":"64","author":"Fox","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1017\/S1461145701002310","article-title":"Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide","volume":"4","author":"Friedhoff","year":"2001","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib121","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3233\/JAD-2012-121537","article-title":"Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes","volume":"33","author":"Froestl","year":"2013","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib122","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.neuropharm.2009.12.020","article-title":"Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer's disease","volume":"58","author":"Fu","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib123","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1523\/JNEUROSCI.4353-06.2007","article-title":"Nonsteroidal anti-inflammatory drugs promote axon regeneration via RhoA inhibition","volume":"27","author":"Fu","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib124","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/0023210-200822120-00004","article-title":"Neurotrophic factors in neurodegenerative disorders: potential for therapy","volume":"22","author":"Fumagalli","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib125","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3233\/JAD-2010-1385","article-title":"Expression of Somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients","volume":"20","author":"Gahete","year":"2010","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib126","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/WAD.0b013e31815d1048","article-title":"Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals","volume":"21","author":"Galasko","year":"2007","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib127","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archneurol.2012.85","article-title":"Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures","volume":"69","author":"Galasko","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2012.12.013","article-title":"Immunotherapy against amyloid pathology in Alzheimer's disease","author":"Galimberti","year":"2013","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0955-0674(00)00172-1","article-title":"Going new places using an old MAP: tau, microtubules and human neurodegenerative disease","volume":"13","author":"Garcia","year":"2001","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib130","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bcp.2009.07.028","article-title":"Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells","volume":"79","author":"Garcia-Martinez","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib131","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","article-title":"Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study","volume":"13","author":"Gauthier","year":"2009","journal-title":"J.\u00a0Nutr. Health Aging"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib132","doi-asserted-by":"crossref","first-page":"P211","DOI":"10.1016\/j.jalz.2012.05.588","article-title":"Failure analysis of dimebon using mechanistic disease modeling: lessons for clinical development of new Alzheimer's disease therapies","volume":"8","author":"Geerts","year":"2012","journal-title":"Alzheimer's Demen."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib133","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archneurol.2010.229","article-title":"A\u00a0randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease","volume":"68","author":"Geldmacher","year":"2011","journal-title":"Arch. Neurol."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2013.07.004_bib134","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1471-4159.2011.07476.x","article-title":"Developing beta-secretase inhibitors for treatment of Alzheimer's disease","volume":"120","author":"Ghosh","year":"2012","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib135","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.neuropharm.2009.01.012","article-title":"Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1\/GluN2A) receptors","volume":"56","author":"Gilling","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib136","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib137","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00018-009-0233-x","article-title":"The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition","volume":"67","author":"Giommarelli","year":"2010","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib138","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.2174\/138161211795589373","article-title":"NAP (davunetide) provides functional and structural neuroprotection","volume":"17","author":"Gozes","year":"2011","journal-title":"Curr. Pharm. Des."},{"issue":"Suppl.\u00a03","key":"10.1016\/j.neuropharm.2013.07.004_bib139","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1471-2202-9-S3-S3","article-title":"NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42)","volume":"9","author":"Gozes","year":"2008","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib140","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/FBP.0b013e328343d804","article-title":"Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity","volume":"22","author":"Gravius","year":"2011","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib141","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lfs.2008.05.011","article-title":"Melatonin prevents amyloid protofibrillar induced oxidative imbalance and biogenic amine catabolism","volume":"83","author":"Gunasingh","year":"2008","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib142","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3233\/JAD-2010-100279","article-title":"Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease","volume":"21","author":"Guntert","year":"2010","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib143","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-3-7091-7508-8_30","article-title":"Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study","volume":"54","author":"Gutzmann","year":"1998","journal-title":"J.\u00a0Neural Transm. Suppl."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib144","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.08m04606","article-title":"Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study","volume":"70","author":"Hampel","year":"2009","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1532-5415.2009.02067.x","article-title":"Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus","volume":"57","author":"Hanyu","year":"2009","journal-title":"J.\u00a0Am. Geriatr. Soc."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib146","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1212\/01.wnl.0000265223.25679.2a","article-title":"Does NSAID use modify cognitive trajectories in the elderly? the Cache County study","volume":"69","author":"Hayden","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neuropharm.2013.07.004_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yhbeh.2013.04.009","article-title":"A\u00a0novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease","volume":"64","author":"He","year":"2013","journal-title":"Horm. Behav."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib148","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1046\/j.1471-4159.2000.740777.x","article-title":"Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists","volume":"74","author":"Hellstrom-Lindahl","year":"2000","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib149","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/gps.2766","article-title":"Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD","volume":"27","author":"Hellweg","year":"2012","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib150","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2174\/138945012800398973","article-title":"alpha7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both?","volume":"13","author":"Hernandez","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib151","doi-asserted-by":"crossref","first-page":"8354","DOI":"10.1523\/JNEUROSCI.0616-08.2008","article-title":"Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice","volume":"28","author":"Hickman","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib152","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/09553008114551581","article-title":"Tl2+ and Ag2+ metal-ion-induced oxidation of methionine in aqueous solution. A pulse radiolysis study","volume":"40","author":"Hiller","year":"1981","journal-title":"Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib153","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejphar.2006.09.049","article-title":"SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models","volume":"553","author":"Hirst","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib154","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3233\/JAD-2009-0916","article-title":"Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration","volume":"16","author":"Ho","year":"2009","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib155","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib156","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/cn2000469","article-title":"ACS chemical neuroscience molecule spotlight on ELND006: another gamma-secretase inhibitor fails in the clinic","volume":"2","author":"Hopkins","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib157","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1106668","article-title":"Donepezil and memantine for moderate-to-severe Alzheimer's disease","volume":"366","author":"Howard","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib158","series-title":"Clinical Trials for Disease-modifying Drugs Such as BACE Inhibitors","first-page":"197","author":"Hsu","year":"2010"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib159","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nbd.2008.10.007","article-title":"GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals","volume":"33","author":"Hu","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib160","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.arr.2010.05.003","article-title":"Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease","volume":"9","author":"Hung","year":"2010","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib161","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/archneurol.2009.46","article-title":"Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease","volume":"66","author":"Ikonomovic","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib162","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3233\/JAD-2009-1092","article-title":"Why did tarenflurbil fail in Alzheimer's disease?","volume":"17","author":"Imbimbo","year":"2009","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib163","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1517\/13543784.2011.550572","article-title":"Therapeutic intervention for Alzheimer's disease with gamma-secretase inhibitors: still a viable option?","volume":"20","author":"Imbimbo","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib164","article-title":"Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?","volume":"2","author":"Imbimbo","year":"2010","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib165","doi-asserted-by":"crossref","first-page":"8754","DOI":"10.1073\/pnas.0710823105","article-title":"Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade","volume":"105","author":"Jacobsen","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib166","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/35055104","article-title":"Protein S-nitrosylation: a physiological signal for neuronal nitric oxide","volume":"3","author":"Jaffrey","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib167","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1074\/jbc.M110.172411","article-title":"A\u03b242 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete A\u03b242 species","volume":"286","author":"Jan","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib168","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.febslet.2008.11.053","article-title":"Ovine colostrum nanopeptide affects amyloid beta aggregation","volume":"583","author":"Janusz","year":"2009","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib169","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2174\/156720510791162377","article-title":"Colostral proline-rich polypeptides\u2013immunoregulatory properties and prospects of therapeutic use in Alzheimer's disease","volume":"7","author":"Janusz","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib170","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.neuroscience.2012.02.046","article-title":"Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type","volume":"210","author":"Javed","year":"2012","journal-title":"Neuroscience"},{"issue":"7","key":"10.1016\/j.neuropharm.2013.07.004_bib171","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/aps.2013.7","article-title":"Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease","volume":"34","author":"Jia","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib172","doi-asserted-by":"crossref","first-page":"12079","DOI":"10.1523\/JNEUROSCI.3345-09.2009","article-title":"Chemical manipulation of hsp70 ATPase activity regulates tau stability","volume":"29","author":"Jinwal","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib173","doi-asserted-by":"crossref","first-page":"1161S","DOI":"10.3945\/ajcn.112.034611","article-title":"A\u00a0possible role for lutein and zeaxanthin in cognitive function in the elderly","volume":"96","author":"Johnson","year":"2012","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib174","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/rej.2006.9.169","article-title":"Extracellular redox state: refining the definition of oxidative stress in aging","volume":"9","author":"Jones","year":"2006","journal-title":"Rejuvenation Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib175","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/alzrt49","article-title":"Dimebon disappointment","volume":"2","author":"Jones","year":"2010","journal-title":"Alzheimers Res. Ther."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2013.07.004_bib176","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1097\/00002093-200000001-00006","article-title":"Nerve growth factor treatment in dementia","volume":"14","author":"Jonhagen","year":"2000","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib177","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/1028415031000111282","article-title":"Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model","volume":"6","author":"Joseph","year":"2003","journal-title":"Nutr. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib178","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.mcn.2008.07.010","article-title":"Nuclear factor erythroid 2-related factor 2 protects against beta amyloid","volume":"39","author":"Kanninen","year":"2008","journal-title":"Mol. Cell Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib179","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1073\/pnas.90.8.3383","article-title":"Role of nitric oxide in interleukin 2-induced corticotropin-releasing factor release from incubated hypothalami","volume":"90","author":"Karanth","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib180","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neuint.2008.10.008","article-title":"Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease","volume":"54","author":"Karuppagounder","year":"2009","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib181","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.3390\/molecules15117792","article-title":"Nutraceutical antioxidants as novel neuroprotective agents","volume":"15","author":"Kelsey","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib182","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1074\/jbc.M009093200","article-title":"Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties","volume":"276","author":"Kelso","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib183","first-page":"59","article-title":"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats","volume":"14","author":"Khalili","year":"2010","journal-title":"Iran Biomed. J."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib184","doi-asserted-by":"crossref","first-page":"13541","DOI":"10.1074\/jbc.M008035200","article-title":"alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity","volume":"276","author":"Kihara","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib185","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.tips.2008.07.001","article-title":"A\u00a0role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory","volume":"29","author":"King","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib186","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/bmj.322.7300.1447","article-title":"Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study","volume":"322","author":"Kivipelto","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib187","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3233\/JAD-2012-120124","article-title":"Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors","volume":"30","author":"Klugman","year":"2012","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib188","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cmdc.200900045","article-title":"Searching for disease modifiers-PKC activation and HDAC inhibition \u2013 a dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress","volume":"4","author":"Kozikowski","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib189","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1089\/ars.2011.4279","article-title":"The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease","volume":"17","author":"Kupershmidt","year":"2012","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib190","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1083\/jcb.106.2.375","article-title":"Genomic organization and biosynthesis of secreted and cytoplasmic forms of gelsolin","volume":"106","author":"Kwiatkowski","year":"1988","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib191","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.brainresbull.2005.06.002","article-title":"Nitric oxide pathway is an important modulator of heat loss in rats during exercise","volume":"67","author":"Lacerda","year":"2005","journal-title":"Brain Res. Bull"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib192","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1749-6632.2000.tb06365.x","article-title":"Lipoproteins in the central nervous system","volume":"903","author":"Ladu","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib193","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1523\/JNEUROSCI.3326-09.2010","article-title":"In the adult hippocampus, chronic nerve growth factor deprivation shifts GABAergic signaling from the hyperpolarizing to the depolarizing direction","volume":"30","author":"Lagostena","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib194","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/156720507780362164","article-title":"How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the \u201cLEARn\u201d model (latent early-life associated regulation) may explain the triggering of AD","volume":"4","author":"Lahiri","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib195","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10522-008-9162-6","article-title":"Early-life events may trigger biochemical pathways for Alzheimer's disease: the \u201cLEARn\u201d model","volume":"9","author":"Lahiri","year":"2008","journal-title":"Biogerontology"},{"issue":"9","key":"10.1016\/j.neuropharm.2013.07.004_bib196","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/npp.2013.70","article-title":"Blockade of tau hyperphosphorylation and abeta generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and sigma receptor agonist, in a nontransgenic mouse model of Alzheimer's disease","volume":"38","author":"Lahmy","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib197","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","article-title":"Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial","volume":"7","author":"Lannfelt","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib198","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2174\/156720511796717177","article-title":"Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies","volume":"8","author":"Lasagna-Reeves","year":"2011","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib199","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00702-010-0433-4","article-title":"The role of microglia in amyloid clearance from the AD brain","volume":"117","author":"Lee","year":"2010","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib200","doi-asserted-by":"crossref","first-page":"16007","DOI":"10.1074\/jbc.275.21.16007","article-title":"Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality","volume":"275","author":"Lee","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib201","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.neurobiolaging.2004.01.005","article-title":"The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice","volume":"25","author":"Lee","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib202","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.addr.2009.07.016","article-title":"The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start?","volume":"61","author":"Lee","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib203","doi-asserted-by":"crossref","first-page":"e40326","DOI":"10.1371\/journal.pone.0040326","article-title":"Memantine inhibits alpha3beta2-nAChRs-mediated nitrergic neurogenic vasodilation in porcine basilar arteries","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib204","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/sj.clpt.6100242","article-title":"Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients","volume":"83","author":"Lefevre","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib205","first-page":"PI93","article-title":"Colostrinin proline-rich polypeptide complex from ovine colostrum\u2013a long-term study of its efficacy in Alzheimer's disease","volume":"8","author":"Leszek","year":"2002","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib206","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.chembiol.2010.08.014","article-title":"Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models","volume":"17","author":"Leyva","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib207","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.21053","article-title":"Simvastatin enhances learning and memory independent of amyloid load in mice","volume":"60","author":"Li","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib208","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3233\/JAD-2010-101332","article-title":"Secretase-independent and RhoGTPase\/PAK\/ERK-dependent regulation of cytoskeleton dynamics in astrocytes by NSAIDs and derivatives","volume":"22","author":"Lichtenstein","year":"2010","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib209","doi-asserted-by":"crossref","first-page":"8370","DOI":"10.1523\/JNEUROSCI.21-21-08370.2001","article-title":"The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse","volume":"21","author":"Lim","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib210","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4155\/fmc.10.291","article-title":"GABAergic drugs and Alzheimer's disease","volume":"3","author":"Limon","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib211","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/aje\/kwf074","article-title":"Risk factors for Alzheimer's disease: a prospective analysis from the Canadian study of health and aging","volume":"156","author":"Lindsay","year":"2002","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib212","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/sj.cdd.4401344","article-title":"Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine","volume":"11","author":"Lipton","year":"2004","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib213","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1523\/JNEUROSCI.5924-12.2013","article-title":"MER5101, a novel Abeta1-15:DT conjugate vaccine, generates a robust anti-abeta antibody response and attenuates abeta pathology and cognitive deficits in APPswe\/PS1DeltaE9 transgenic mice","volume":"33","author":"Liu","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib214","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1073\/pnas.0400348101","article-title":"O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease","volume":"101","author":"Liu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib215","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neulet.2006.07.020","article-title":"Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance","volume":"406","author":"Liu","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib216","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3233\/JAD-2009-1033","article-title":"Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental","volume":"17","author":"Lloret","year":"2009","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib217","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jplph.2005.04.012","article-title":"Vitamin E bioavailability in humans","volume":"162","author":"Lodge","year":"2005","journal-title":"J.\u00a0Plant Physiol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib218","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1016\/j.bmcl.2012.08.051","article-title":"Discovery, oral pharmacokinetics and in\u00a0vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation","volume":"22","author":"Long","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib219","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/jnnp.2008.158964","article-title":"Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease","volume":"80","author":"Lopez","year":"2009","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib220","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archneur.63.2.nct50002","article-title":"Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men","volume":"63","author":"Lu","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib221","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/exnr.2001.7732","article-title":"Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism","volume":"171","author":"Lue","year":"2001","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib222","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1073\/pnas.0701055104","article-title":"Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies","volume":"104","author":"Luo","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.neuropharm.2013.07.004_bib223","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1021\/cn400011f","article-title":"Abeta42-Binding peptoids as amyloid aggregation inhibitors and detection ligands","volume":"4","author":"Luo","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib224","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1074\/jbc.M112.393751","article-title":"Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice","volume":"288","author":"Ma","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib225","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/jnnp-2012-302589","article-title":"Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-beta peptide and tau levels: target engagement, tolerability and pharmacokinetics in humans","volume":"83","author":"Maccecchini","year":"2012","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib226","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.addr.2008.04.015","article-title":"Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease","volume":"60","author":"Maczurek","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib227","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12031-009-9269-5","article-title":"Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy","volume":"40","author":"Maelicke","year":"2010","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib228","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/gps.2562","article-title":"SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study","volume":"26","author":"Maher-Edwards","year":"2011","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib229","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2174\/156720510791383831","article-title":"Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease","volume":"7","author":"Maher-Edwards","year":"2010","journal-title":"Curr. Alzheimer Res."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.neuropharm.2013.07.004_bib230","doi-asserted-by":"crossref","first-page":"S609","DOI":"10.3233\/JAD-2010-100564","article-title":"Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons","volume":"20","author":"Manczak","year":"2010","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib231","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1083\/jcb.200104008","article-title":"S-Nitrosylation of mitochondrial caspases","volume":"154","author":"Mannick","year":"2001","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib232","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s11064-011-0684-y","article-title":"Distribution of serotonin receptor of type 6 (5-HT(6)) in human brain post-mortem. A pharmacology, autoradiography and immunohistochemistry study","volume":"37","author":"Marazziti","year":"2012","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib233","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1471-4159.2008.05396.x","article-title":"Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing","volume":"106","author":"Marcade","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib234","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1523\/JNEUROSCI.23-06-01992.2003","article-title":"Neprilysin gene transfer reduces human amyloid pathology in transgenic mice","volume":"23","author":"Marr","year":"2003","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib235","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1046\/j.1471-4159.1997.69051995.x","article-title":"Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta","volume":"69","author":"Martel","year":"1997","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib236","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/jpet.109.152975","article-title":"Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease","volume":"331","author":"Martone","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib237","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/sj.bjp.0705559","article-title":"Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors","volume":"140","author":"Maskell","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib238","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1172\/JCI41356","article-title":"Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents","volume":"120","author":"Massa","year":"2010","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib239","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1385\/JMN\/31:02:165","article-title":"Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage","volume":"31","author":"Matsuoka","year":"2007","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib240","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1124\/jpet.107.130526","article-title":"A\u00a0neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease","volume":"325","author":"Matsuoka","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib241","doi-asserted-by":"crossref","first-page":"38992","DOI":"10.1074\/jbc.M112.348037","article-title":"A\u00a0novel inhibitor of amyloid beta (Abeta) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease","volume":"287","author":"McKoy","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib242","first-page":"CD003154","article-title":"Memantine for dementia","author":"McShane","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib243","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ajpath.2011.04.041","article-title":"Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline","volume":"179","author":"Medeiros","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib244","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1476-5381.2008.00075.x","article-title":"Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice","volume":"157","author":"Medhurst","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib245","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib246","doi-asserted-by":"crossref","first-page":"H1918","DOI":"10.1152\/ajpheart.00416.2007","article-title":"The central role of adenosine in statin-induced ERK1\/2, Akt, and eNOS phosphorylation","volume":"293","author":"Merla","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib247","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2012.07.032","article-title":"Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid beta1-40","volume":"692","author":"Miguel-Hidalgo","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib248","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1601-183X.2004.00112.x","article-title":"The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials","volume":"4","author":"Mohs","year":"2005","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib249","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-2006-9410","article-title":"Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease","volume":"9","author":"Morris","year":"2006","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib250","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00002093-199903000-00003","article-title":"Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type","volume":"13","author":"Moss","year":"1999","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib251","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/bcp.12018","article-title":"A\u00a0randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease","volume":"75","author":"Moss","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib252","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1124\/jpet.110.174458","article-title":"Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease","volume":"336","author":"Motawaj","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib253","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2515\/therapie\/2010058","article-title":"The histaminergic system: a target for innovative treatments of cognitive deficits","volume":"65","author":"Motawaj","year":"2010","journal-title":"Therapie"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib254","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.neuint.2008.12.001","article-title":"Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in\u00a0vitro","volume":"54","author":"Mousavi","year":"2009","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib255","doi-asserted-by":"crossref","first-page":"H1737","DOI":"10.1152\/ajpheart.00269.2007","article-title":"Statins prevent cholinesterase inhibitor blockade of sympathetic alpha7-nAChR-mediated currents in rat superior cervical ganglion neurons","volume":"293","author":"Mozayan","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib256","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1159\/000343479","article-title":"Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias","volume":"2","author":"Muayqil","year":"2012","journal-title":"Dement Geriatr. Cogn. Dis. Extra"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib257","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1146\/annurev.pharmtox.47.120505.105110","article-title":"Targeting antioxidants to mitochondria by conjugation to lipophilic cations","volume":"47","author":"Murphy","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib258","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbr.2010.11.053","article-title":"Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: involvement of dopamine D2 and 5-HT2A receptors","volume":"218","author":"Nakaya","year":"2011","journal-title":"Behav. Brain Res."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2013.07.004_bib259","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1471-4159.2011.07510.x","article-title":"Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?","volume":"120","author":"Nalivaeva","year":"2012","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib260","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2174\/1567205011310030003","article-title":"The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation","volume":"10","author":"Nathan","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib261","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1021\/bi700411k","article-title":"Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization","volume":"46","author":"Necula","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib262","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s12603-009-0249-9","article-title":"Dietary folate, vitamin B-12, vitamin B-6 and incident Alzheimer's disease: the cache county memory, health and aging study","volume":"13","author":"Nelson","year":"2009","journal-title":"J.\u00a0Nutr. Health Aging"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib263","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3233\/JAD-2012-121447","article-title":"Modulation of alpha7 nicotinic acetylcholine receptor and fibrillar amyloid-beta interactions in Alzheimer's disease brain","volume":"33","author":"Ni","year":"2013","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib264","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1523\/JNEUROSCI.3348-08.2008","article-title":"Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist","volume":"28","author":"Nicolakakis","year":"2008","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib265","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/nature07767","article-title":"APP binds DR6 to trigger axon pruning and neuron death via distinct caspases","volume":"457","author":"Nikolaev","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib266","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/1531-8249(200012)48:6<913::AID-ANA12>3.0.CO;2-S","article-title":"The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease","volume":"48","author":"Nitsch","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib267","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00228-012-1459-3","article-title":"Has inhibition of Abeta production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of gamma-secretase inhibitor data","volume":"69","author":"Niva","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib268","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1073\/pnas.0500466102","article-title":"Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in\u00a0vivo","volume":"102","author":"Noble","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib269","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0006-8993(88)90765-2","article-title":"Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced","volume":"451","author":"Novelli","year":"1988","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib270","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/156720510790691100","article-title":"From anti-allergic to anti-Alzheimer's: molecular pharmacology of Dimebon","volume":"7","author":"Okun","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib271","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1600-079X.2009.00692.x","article-title":"Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease","volume":"47","author":"Olcese","year":"2009","journal-title":"J.\u00a0Pineal Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib272","doi-asserted-by":"crossref","first-page":"16419","DOI":"10.1523\/JNEUROSCI.3317-10.2010","article-title":"Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits","volume":"30","author":"Oliveira","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib273","first-page":"185","article-title":"Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area","volume":"153","author":"Orgogozo","year":"1997","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib274","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib275","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib276","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2125.2012.04472.x","article-title":"Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers","volume":"75","author":"Othman","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib277","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.amjopharm.2012.08.002","article-title":"The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study","volume":"10","author":"Padala","year":"2012","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib278","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/JGP.0b013e3181cabcf6","article-title":"Methylphenidate for apathy and functional status in dementia of the Alzheimer type","volume":"18","author":"Padala","year":"2010","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib279","doi-asserted-by":"crossref","first-page":"e14015","DOI":"10.1371\/journal.pone.0014015","article-title":"Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease","volume":"5","author":"Parachikova","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib280","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbrc.2011.04.068","article-title":"Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation","volume":"408","author":"Park","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib281","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1212\/WNL.44.6.1090","article-title":"Electron transport chain defects in Alzheimer's disease brain","volume":"44","author":"Parker","year":"1994","journal-title":"Neurology"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.neuropharm.2013.07.004_bib282","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1007\/s100720200086","article-title":"Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors","volume":"23","author":"Parnetti","year":"2002","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib283","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/156720510790274464","article-title":"Nicotinic acetylcholine receptor interaction with beta-amyloid: molecular, cellular, and physiological consequences","volume":"7","author":"Parri","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib284","doi-asserted-by":"crossref","DOI":"10.1007\/s12640-013-9398-z","article-title":"Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease","author":"Parsons","year":"2013","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib285","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2125.2008.03348.x","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects","volume":"67","author":"Patat","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib286","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000022023","article-title":"Differential chromosome sensitivity to 5-azacytidine in Alzheimer's disease","volume":"44","author":"Payao","year":"1998","journal-title":"Gerontology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib287","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/01.JGP.0000224350.82719.83","article-title":"Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial","volume":"14","author":"Peskind","year":"2006","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib288","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","article-title":"Vitamin E and donepezil for the treatment of mild cognitive impairment","volume":"352","author":"Petersen","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib289","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.bjp.0701355","article-title":"The interaction between methylene blue and the cholinergic system","volume":"122","author":"Pfaffendorf","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib290","first-page":"404","article-title":"Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type","volume":"10","author":"Pinto","year":"2011","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib291","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2165\/11203320-000000000-00000","article-title":"Cerebrolysin: a review of its use in dementia","volume":"26","author":"Plosker","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib292","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/156720508783884576","article-title":"Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial","volume":"5","author":"Porsteinsson","year":"2008","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib293","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/FBP.0b013e3283566082","article-title":"Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease","volume":"23","author":"Price","year":"2012","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib294","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.neuropharm.2011.10.024","article-title":"EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors","volume":"62","author":"Prickaerts","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib295","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1523\/JNEUROSCI.0864-09.2009","article-title":"Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model","volume":"29","author":"Puzzo","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib296","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/archneurol.2008.588","article-title":"PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia","volume":"66","author":"Qin","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib297","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jns.2006.02.006","article-title":"Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice","volume":"244","author":"Qu","year":"2006","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib298","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/archneur.61.12.1859","article-title":"Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease","volume":"61","author":"Qu","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib299","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.brainres.2005.01.023","article-title":"Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials","volume":"1037","author":"Quinn","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib300","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1212\/WNL.0b013e318216eb7b","article-title":"A\u00a0phase II trial of huperzine A in mild to moderate Alzheimer disease","volume":"76","author":"Rafii","year":"2011","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.neuropharm.2013.07.004_bib301","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.arcmed.2012.11.008","article-title":"Alzheimer's disease: critical notes on the history of a medical concept","volume":"43","author":"Ramirez-Bermudez","year":"2012","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib302","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0304-3940(01)01872-9","article-title":"The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2\/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner","volume":"306","author":"Rammes","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib408","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157015908783769671","article-title":"Pharmacodynamics of memantine: an update. Curr.","volume":"6","author":"Rammes","year":"2008","journal-title":"Neuropharmacol"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib303","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.neuropharm.2011.01.051","article-title":"Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices","volume":"60","author":"Rammes","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib304","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/nen.0b013e31802d6da9","article-title":"Expression of Nrf2 in neurodegenerative diseases","volume":"66","author":"Ramsey","year":"2007","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib305","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","article-title":"Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults","volume":"13","author":"Reger","year":"2008","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib306","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1016\/j.bmcl.2010.12.015","article-title":"Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe","volume":"21","author":"Reid","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib307","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.62.1.66","article-title":"Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study","volume":"62","author":"Reines","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib308","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2007.12.021","article-title":"18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease","volume":"30","author":"Relkin","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib309","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1503\/jpn.110190","article-title":"Glutamate system, amyloid ss peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology","volume":"38","author":"Revett","year":"2013","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib310","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1476-5381.1995.tb13303.x","article-title":"5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases","volume":"114","author":"Reynolds","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib311","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.molcel.2005.12.006","article-title":"A\u00a0nitric oxide signaling pathway controls CREB-mediated gene expression in neurons","volume":"21","author":"Riccio","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib312","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000100875","article-title":"Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine","volume":"23","author":"Riepe","year":"2007","journal-title":"Dement Geriatr. Cogn. Disord."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib313","doi-asserted-by":"crossref","first-page":"T774","DOI":"10.1016\/j.jalz.2008.05.2414","article-title":"P4-344: oral curcumin for the treatment of mild-to-moderate Alzheimer's disease: tolerability and clinical and biomarker efficacy results of a placebo-controlled 24-week study","volume":"4","author":"Ringman","year":"2008","journal-title":"Alzheimer's Demen. The J. Alzheimer's Assoc."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib314","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1471-4159.2007.04832.x","article-title":"GABA(A) receptors in aging and Alzheimer's disease","volume":"103","author":"Rissman","year":"2007","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib315","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","article-title":"Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial","volume":"60","author":"Ritchie","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib316","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pneurobio.2012.06.010","article-title":"The serotonergic system in ageing and Alzheimer's disease","volume":"99","author":"Rodriguez","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib317","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0924-977X(00)00067-5","article-title":"Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study","volume":"10","author":"Rogers","year":"2000","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib318","doi-asserted-by":"crossref","first-page":"e59735","DOI":"10.1371\/journal.pone.0059735","article-title":"Bapineuzumab alters abeta composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy","volume":"8","author":"Roher","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib319","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3233\/JAD-2010-1262","article-title":"Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease","volume":"19","author":"Rojo","year":"2010","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib320","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/1567205011310030001","article-title":"Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies","volume":"10","author":"Rosenmann","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib321","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1001\/archneur.63.10.1459","article-title":"Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein","volume":"63","author":"Rosenmann","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib322","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.neuropharm.2007.07.015","article-title":"A\u00a0selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat","volume":"53","author":"Ross","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib323","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/WAD.0b013e318204b550","article-title":"PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease","volume":"25","author":"Sabbagh","year":"2011","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib324","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/nm1635","article-title":"Clearance of amyloid-beta by circulating lipoprotein receptors","volume":"13","author":"Sagare","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib325","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nm1206","article-title":"Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation","volume":"11","author":"Saito","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib326","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1124\/jpet.107.128959","article-title":"HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1\/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects","volume":"324","author":"Sala","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib327","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A\u00a0phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib328","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/nn.2213","article-title":"Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease","volume":"11","author":"Sanchez-Mejia","year":"2008","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib329","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease","volume":"77","author":"Sano","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib330","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1750-1326-2-17","article-title":"Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau","volume":"2","author":"Santa-Maria","year":"2007","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib331","doi-asserted-by":"crossref","first-page":"e2718","DOI":"10.1371\/journal.pone.0002718","article-title":"Mitochondrial Ca2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs","volume":"3","author":"Sanz-Blasco","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib332","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s12603-009-0217-4","article-title":"Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study","volume":"13","author":"Saumier","year":"2009","journal-title":"J.\u00a0Nutr. Health Aging"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib333","doi-asserted-by":"crossref","first-page":"37046","DOI":"10.1074\/jbc.274.52.37046","article-title":"The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation","volume":"274","author":"Sayas","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib334","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00702-011-0619-4","article-title":"Inhibition of phospholipase A2 in rat brain decreases the levels of total Tau protein","volume":"118","author":"Schaeffer","year":"2011","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib335","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00213-008-1351-0","article-title":"Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease","volume":"202","author":"Schaeffer","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib336","doi-asserted-by":"crossref","first-page":"a006387","DOI":"10.1101\/cshperspect.a006387","article-title":"Treatment strategies targeting amyloid beta-protein","volume":"2","author":"Schenk","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib337","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00702-006-0579-2","article-title":"The significance of the cholinergic system in the brain during aging and in Alzheimer's disease","volume":"113","author":"Schliebs","year":"2006","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib338","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archneurol.2011.69","article-title":"Lack of evidence for the efficacy of memantine in mild Alzheimer disease","volume":"68","author":"Schneider","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib339","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1039\/C0SC00544D","article-title":"N-Aryl-substituted 3-([small beta]-D-glucopyranosyloxy)-2-methyl-4(1H)-pyridinones as agents for Alzheimer's therapy","volume":"2","author":"Scott","year":"2011","journal-title":"Chem. Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib340","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/sj.bjp.0707471","article-title":"Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation","volume":"152","author":"Selenica","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib341","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.1073\/pnas.131152998","article-title":"Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development","volume":"98","author":"Shaw","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib342","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1210\/jc.2011-1802","article-title":"Effect of intranasal insulin on cognitive function: a systematic review","volume":"97","author":"Shemesh","year":"2012","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib343","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuropharm.2011.02.026","article-title":"5-HT(4) receptor agonist mediated enhancement of cognitive function in\u00a0vivo and amyloid precursor protein processing in\u00a0vitro: a pharmacodynamic and pharmacokinetic assessment","volume":"61","author":"Shen","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib344","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib345","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.neuint.2010.03.016","article-title":"H2O2 and PAF mediate Abeta1-42-induced Ca2+ dyshomeostasis that is blocked by EGb761","volume":"56","author":"Shi","year":"2010","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib346","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI10498","article-title":"Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier","volume":"106","author":"Shibata","year":"2000","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib347","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0306-4522(97)00342-4","article-title":"Phospholipase C isozymes in the human brain and their changes in Alzheimer's disease","volume":"82","author":"Shimohama","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib348","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/10715760802644694","article-title":"Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease","volume":"43","author":"Siedlak","year":"2009","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib349","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/WNF.0b013e3181cb577a","article-title":"Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease","volume":"33","author":"Siemers","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib350","doi-asserted-by":"crossref","first-page":"e2466","DOI":"10.1371\/journal.pone.0002466","article-title":"Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome","volume":"3","author":"Skov","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib351","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1073\/pnas.87.7.2452","article-title":"Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy","volume":"87","author":"Slotkin","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib352","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijpharm.2010.01.012","article-title":"Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease","volume":"389","author":"Smith","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib353","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/mds.23148","article-title":"A\u00a0double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease","volume":"25","author":"Snow","year":"2010","journal-title":"Mov Disord."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib354","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2013.07.004_bib355","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/2040622310382817","article-title":"Frontiers in Alzheimer's disease therapeutics","volume":"2","author":"Stone","year":"2011","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib356","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11064-009-0058-x","article-title":"Neuroprotective effect of KB-R7943 against glutamate excitotoxicity is related to mild mitochondrial depolarization","volume":"35","author":"Storozhevykh","year":"2010","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib357","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1212\/01.wnl.0000284596.95156.48","article-title":"NSAID use and dementia risk in the cardiovascular health study: role of APOE and NSAID type","volume":"70","author":"Szekely","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib358","doi-asserted-by":"crossref","first-page":"P84","DOI":"10.1016\/j.jalz.2009.05.216","article-title":"The ADCS valproate neuroprotection trial: primary efficacy and safety results","volume":"5","author":"Tariot","year":"2009","journal-title":"Alzheimer's Demen. The J. Alzheimer's Assoc."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib359","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib360","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","article-title":"Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease","volume":"68","author":"Tariot","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.neuropharm.2013.07.004_bib361","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1517\/14712598.2013.789856","article-title":"Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?","volume":"13","author":"Tayeb","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib362","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1212\/01.WNL.0000096376.03678.C1","article-title":"Idebenone treatment fails to slow cognitive decline in Alzheimer's disease","volume":"61","author":"Thal","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib363","first-page":"37","article-title":"alpha7 nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer's disease","volume":"4","author":"Toyohara","year":"2010","journal-title":"Open Med. Chem. J."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib364","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1212\/01.WNL.0000031421.50369.E7","article-title":"Amount and type of alcohol and risk of dementia: the Copenhagen city heart study","volume":"59","author":"Truelsen","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib365","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm1239","article-title":"A\u00a0phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease","volume":"11","author":"Tuszynski","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib366","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156720509787602852","article-title":"Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders","volume":"6","author":"Vellas","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib367","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1474-4422(12)70206-5","article-title":"Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial","volume":"11","author":"Vellas","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib368","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/156720511795256053","article-title":"EHT0202 in Alzheimer's disease: a 3-Month, randomized, placebo-controlled, double-blind study","volume":"8","author":"Vellas","year":"2011","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib369","doi-asserted-by":"crossref","DOI":"10.1177\/0748233712457439","article-title":"Protective effect of lutein against benzo(a)pyrene-induced oxidative stress in human erythrocytes","author":"Vijayapadma","year":"2012","journal-title":"Toxicol. Ind. Health"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib370","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/cne.20447","article-title":"Serotonin 5-HT4 receptors and their mRNAs in rat and guinea pig brain: distribution and effects of neurotoxic lesions","volume":"484","author":"Vilaro","year":"2005","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib371","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.neurobiolaging.2007.11.014","article-title":"APOE genotype-specific differences in the innate immune response","volume":"30","author":"Vitek","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib372","first-page":"R1562","article-title":"Effect of nitric oxide synthase inhibitors on short-term appetite and food intake in humans","volume":"276","author":"Vozzo","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib373","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3171\/2012.2.JNS11714","article-title":"Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery","volume":"117","author":"Wahlberg","year":"2012","journal-title":"J.\u00a0Neurosurg."},{"issue":"12","key":"10.1016\/j.neuropharm.2013.07.004_bib374","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bcp.2013.04.001","article-title":"Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex","volume":"85","author":"Wallace","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib375","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.2010.05842.x","article-title":"Bioavailability of resveratrol","volume":"1215","author":"Walle","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib376","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1745-7254.2006.00260.x","article-title":"Role of melatonin in Alzheimer-like neurodegeneration","volume":"27","author":"Wang","year":"2006","journal-title":"Acta Pharmacol. Sin"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib377","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1006\/bbrc.1997.6636","article-title":"Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D","volume":"234","author":"Wang","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib378","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3233\/JAD-2011-111874","article-title":"Clioquinol reduces zinc accumulation in neuritic plaques and inhibits the amyloidogenic pathway in AbetaPP\/PS1 transgenic mouse brain","volume":"29","author":"Wang","year":"2012","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib379","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1523\/JNEUROSCI.1357-09.2009","article-title":"Impaired balance of mitochondrial fission and fusion in Alzheimer's disease","volume":"29","author":"Wang","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib380","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jama.1994.03510370044030","article-title":"Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease","volume":"271","author":"Watkins","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib381","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12017-012-8176-z","article-title":"An aqueous orally active vaccine targeted against a RAGE\/AB complex as a novel therapeutic for Alzheimer's disease","volume":"14","author":"Webster","year":"2012","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib382","doi-asserted-by":"crossref","first-page":"31831","DOI":"10.1074\/jbc.M303592200","article-title":"Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity","volume":"278","author":"Weggen","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib383","first-page":"157","article-title":"TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease","author":"Weinstock","year":"2000","journal-title":"J.\u00a0Neural Transm. Suppl."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib384","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0531-5565(02)00029-3","article-title":"Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals","volume":"37","author":"Weksler","year":"2002","journal-title":"Exp. Gerontol."},{"issue":"18","key":"10.1016\/j.neuropharm.2013.07.004_bib385","doi-asserted-by":"crossref","first-page":"16504","DOI":"10.1074\/jbc.M110.208447","article-title":"Alternative mitochondrial electron transfer as a novel strategy for neuroprotection","volume":"286","author":"Wen","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib386","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4088\/JCP.v69n0302","article-title":"Memantine for agitation\/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies","volume":"69","author":"Wilcock","year":"2008","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib387","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib388","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1212\/01.wnl.0000281847.17519.e0","article-title":"IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease","volume":"69","author":"Winblad","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib389","doi-asserted-by":"crossref","first-page":"T167","DOI":"10.1016\/j.jalz.2008.05.438","article-title":"O3-04-07: tau aggregation inhibitor (TAI) therapy with rember\u2122 arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks","volume":"4","author":"Wischik","year":"2008","journal-title":"Alzheimer's Demen. The J. Alzheimer's Assoc."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib390","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1358\/dot.2006.42.5.973584","article-title":"Tramiprosate","volume":"42","author":"Wright","year":"2006","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib391","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s11596-010-0559-5","article-title":"A\u00a0meta-analysis of mood stabilizers for Alzheimer's disease","volume":"30","author":"Xiao","year":"2010","journal-title":"J.\u00a0Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib392","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2012.02.002","article-title":"Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease","volume":"97","author":"Xu","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib393","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1074\/jbc.M404751200","article-title":"Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in\u00a0vivo","volume":"280","author":"Yang","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib394","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3233\/JAD-2012-121294","article-title":"Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes","volume":"33","author":"Yang","year":"2013","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib395","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0006-8993(01)03008-6","article-title":"Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain","volume":"919","author":"Yasojima","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib396","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/sj.gt.3301566","article-title":"Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element \u2018decoy\u2019 of nuclear factor-kappaB binding site as a novel molecular strategy","volume":"8","author":"Yoshimura","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib397","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tips.2004.11.007","article-title":"Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders","volume":"26","author":"Youdim","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib398","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1023\/A:1015131516649","article-title":"Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]","volume":"21","author":"Youdim","year":"2001","journal-title":"Cell Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.neuropharm.2013.07.004_bib399","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/1871523011312020003","volume":"12","author":"Yu","year":"2013","journal-title":"Antiinflamm. Antiallergy Agents Med. Chem."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib400","doi-asserted-by":"crossref","first-page":"e35277","DOI":"10.1371\/journal.pone.0035277","article-title":"Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation","volume":"7","author":"Yu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib401","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1745-7254.2007.00618.x","article-title":"Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes","volume":"28","author":"Yue","year":"2007","journal-title":"Acta Pharmacol. Sin"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib402","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1001\/jama.288.17.2123","article-title":"Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study","volume":"288","author":"Zandi","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib403","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.0406361102","article-title":"Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib404","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10571-007-9163-z","article-title":"Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase","volume":"28","author":"Zhang","year":"2008","journal-title":"Cell Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-394816-8.00001-5","article-title":"Hsp90 modulation for the treatment of Alzheimer's disease","volume":"64","author":"Zhao","year":"2012","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.07.004_bib406","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.bbadis.2006.10.014","article-title":"Alzheimer disease, the two-hit hypothesis: an update","volume":"1772","author":"Zhu","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2013.07.004_bib407","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1471-4159.2004.02385.x","article-title":"Clearing amyloid through the blood-brain barrier","volume":"89","author":"Zlokovic","year":"2004","journal-title":"J.\u00a0Neurochem."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813003195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813003195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T12:07:11Z","timestamp":1688386031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390813003195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":408,"alternative-id":["S0028390813003195"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.07.004","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutics of Alzheimer's disease: Past, present and future","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}